Us Bancorp \De\ Travere Therapeutics, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 7,509 shares of TVTX stock, worth $153,634. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,509

Previous 7,609 1.31%

Holding current value

$153,634

Previous $62,000 69.35%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$7.89 - $15.21 $789 - $1,521	-100 Reduced 1.31%	7,509 $105,000
Q2 2024 Aug 06, 2024	BUY	$5.26 - $8.28 $35,194 - $55,401	6,691 Added 728.87%	7,609 $62,000
Q1 2024 May 07, 2024	BUY	$7.18 - $9.82 $2,175 - $2,975	303 Added 49.27%	918 $7,000
Q4 2023 Feb 09, 2024	BUY	$5.44 - $9.5 $2,943 - $5,139	541 Added 731.08%	615 $5,000
Q2 2023 Aug 09, 2023	SELL	$15.3 - $22.61 $4,498 - $6,647	-294 Reduced 79.89%	74 $1,000
Q1 2023 May 09, 2023	BUY	$17.82 - $22.89 $5,239 - $6,729	294 Added 397.3%	368 $8,000
Q4 2022 Feb 13, 2023	SELL	$18.47 - $26.14 $609 - $862	-33 Reduced 30.84%	74 $1,000
Q3 2022 Oct 27, 2022	BUY	$22.91 - $28.63 $137 - $171	6 Added 5.94%	107 $3,000
Q2 2022 Aug 01, 2022	SELL	$20.94 - $30.01 $29,022 - $41,593	-1,386 Reduced 93.21%	101 $2,000
Q1 2022 May 11, 2022	BUY	$23.61 - $30.6 $32,723 - $42,411	1,386 Added 1372.28%	1,487 $38,000
Q3 2021 Nov 10, 2021	SELL	$12.98 - $25.03 $337 - $650	-26 Reduced 20.47%	101 $2,000
Q2 2021 Aug 05, 2021	BUY	$14.11 - $26.4 $366 - $686	26 Added 25.74%	127 $2,000
Q4 2020 Feb 04, 2021	BUY	$19.17 - $27.87 $1,936 - $2,814	101 New	101 $3,000

Others Institutions Holding TVTX

# of Institutions

196

Shares Held

84.9M

Call Options Held

776K

Put Options Held

900K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.31B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account